ATRC AtriCure Inc.

AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference

MASON, Ohio--(BUSINESS WIRE)--

(), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference.

AtriCure’s management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X (formerly Twitter) .

EN
29/07/2024

Underlying

ATRCAtriCure Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AtriCure Inc.

 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Announces that the First Patient has been Treated with the Re...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of AtriCure’s AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for ...

August 27, 2024 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure bénéficie d'une indication élargie du marquage CE pour les di...

MASON, Ohio--(BUSINESS WIRE)-- ( ), l'un des principaux innovateurs dans le domaine des traitements chirurgicaux et des traitements contre la fibrillation auriculaire (AFib), la gestion de l'appendice auriculaire gauche (LAA) et la gestion de la douleur postopératoire, a annoncé aujourd'hui avoir reçu une indication élargie pour AtriClip ® dans les pays d'Europe bénéficiant du marquage CE. Le produit est désormais indiqué chez les patients présentant un risque élevé de thromboembolie et pour lesquels l'exclusion de l'appendice auriculaire gauche est justifiée. Les dispositifs de la famille...

August 22, 2024 1 FR
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices fo...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received an expanded indication for the AtriClip® in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage exclusion is warranted. The AtriClip family of devices are innovative solutions designed to exclude, electrically isolate, and eventually eliminate the left atrial appendage...

August 22, 2024 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Reports Second Quarter 2024 Financial Results

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results. “Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip® franchises, as we continued to deliver exceptional patient outcomes across all therapies, while driving positive cash flow,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “Entering the second half of 20...

July 30, 2024 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Participate in the Canaccord Genuity 44th Annual Global Gr...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference. AtriCure’s management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at About AtriCure AtriCure, Inc. provides...

July 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch